Suppression of endothelial ceramide de novo biosynthesis by Nogo-B contributes to cardiometabolic diseases

92

Suppression of endothelial ceramide de novo biosynthesis by Nogo-B contributes to cardiometabolic diseases

Tags:

Previous Article

ALS drug effectively treats Alzheimer’s disease

Inhibition of ceramide synthesis contributes to cardiometabolic diseases

Related Posts

Deletion of PTP1B in cardiomyocytes alters cardiac metabolic signaling to protect against cardiomyopathy induced by a high-fat diet

Deletion of PTP1B in cardiomyocytes alters cardiac meta...

109

Allosteric antibodies: a novel paradigm in drug discovery

Allosteric antibodies: a novel paradigm in drug discovery

97

A chaperone-proteasome-based fragmentation machinery is essential for aggrephagy

A chaperone-proteasome-based fragmentation machinery is...

41